Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39 + CD8 + T cells

1 Dec 2020

Abstract excerpt

Objective It remains controversial whether tumour mutational burden (TMB) or neoantigens are prognostic markers in hepatocellular carcinoma (HCC). This study aimed to define the function of TMB or neoantigens in antitumour immunotherapy. Design Neoantigens of patients (n=56) were analysed by pVAC tools with major histocompatibility complex-1 (MHC-I) algorithms based on whole exome sequencing and neoantigens with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Hepatocellular Carcinoma Treatment and Prognosis
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33262196
DOI: 10.1136/gutjnl-2020-322196

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39 + CD8 + T cellsPMID 33262196Read ↗

Profiling of hepatocellular carcinoma neoantigens reveals immune microenvironment and clonal evolution related patternsSemantic proximity Read ↗

Neoantigens as potential vaccines in hepatocellular carcinomaSemantic proximity Read ↗

Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigenSemantic proximity Read ↗

Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma.Semantic proximity Read ↗

Decoding Neoantigen-encoding Tumor-Specific Transcripts Unveils a Shared Target Reservoir for Immunotherapy in Hepatocellular CarcinomaSemantic proximity Read ↗

Immunogenicity of Neoantigens in Colorectal Cancer: Potential Influence of Tumor Mutation Burden, Stages, and MetastasisSemantic proximity Read ↗

Identification of WDFY3 Neoantigens as Prognostic Markers in Longterm Survivors of Extrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.Semantic proximity Read ↗

Neoantigens heterogeneity as a prognostic marker in patients with resected intrahepatic cholangiocarcinomaSemantic proximity Read ↗

The common neoantigens in colorectal cancer are predicted and validated to be presented or immunogenicSemantic proximity Read ↗

Neoantigen polypeptide vaccines induce effective antitumor response in colorectal cancerSemantic proximity Read ↗

Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.